Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization
Journal of Clinical Medicine · 25.05.2024 · 13 (11) · 3096
DOI: 10.3390/jcm13113096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.05.2024. Verfasst von Krzysztof L Bryniarski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of interventional Cardiology, Thoraxcenter, Cardiovascular Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherland…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherosclerosis is the predominant underlying etiopathology of coronary artery disease. Changes in plaque phenotype from stable to high risk may spur future major adverse cardiac events (MACE). Different pharmacological therapies have been implemented to mitigate this risk. Over the last two decades, intravascular imaging modalities have emerged in clinical studies to clarify how these therapies may affect the composition and burden of coronary plaques. Lipid-lowering agents, such as statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors, were shown not only to reduce low-density lipoprotein levels and MACE but also to directly affect features of coronary plaque vulnerability. Studies have demonstrated that lipid-lowering therapy reduces the percentage of atheroma volume and number of macrophages and increases fibrous cap thickness. Future studies should answer the question of whether pharmacological plaque stabilization may be sufficient to mitigate the risk of MACE for selected groups of patients with atherosclerotic coronary disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of interventional Cardiology, Thoraxcenter, Cardiovascular Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
- Department of Interventional Cardiology, Jagiellonian University Medical College, Institute of Cardiology, St. John Paul II Hospital, 31-202 Krakow, Poland.
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Department of Interventional Cardiology, Imelda Hospital, 2820 Bonheiden, Belgium.
- Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Pawel Gasior, Pawel Kleczynski, Ik-Kyung Jang
Zitieren
APA
Bryniarski, K. L., den Dekker, W., Legutko, J., Gasior, P., Tahon, J., Diletti, R., Wilschut, J. M., Nuis, R. J., Daemen, J., Kleczynski, P., Van Mieghem, N. M., & Jang, I. K. (2024). Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization. Journal of Clinical Medicine, 13(11), 3096. https://doi.org/10.3390/jcm13113096
Vancouver
Bryniarski KL, den Dekker W, Legutko J, Gasior P, Tahon J, Diletti R, et al. Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization. Journal of Clinical Medicine. 2024;13(11):3096. doi:10.3390/jcm13113096
BibTeX
@article{Bryniarski2024,
author = {Bryniarski, Krzysztof L and den Dekker, Wijnand and Legutko, Jacek and Gasior, Pawel and Tahon, Jeroen and Diletti, Roberto and Wilschut, Jeroen M and Nuis, Rutger-Jan and Daemen, Joost and Kleczynski, Pawel and Van Mieghem, Nicolas M and Jang, Ik-Kyung},
title = {Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {11},
pages = {3096},
doi = {10.3390/jcm13113096}
}
EUVIMED